These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 2973587)

  • 21. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age.
    van den Anker JN; Schoemaker RC; Hop WC; van der Heijden BJ; Weber A; Sauer PJ; Neijens HJ; de Groot R
    Clin Pharmacol Ther; 1995 Dec; 58(6):650-9. PubMed ID: 8529330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. POPULATION PHARMACOKINETICS OF CEFTAZIDIME AFTER A SINGLE SUBCUTANEOUS INJECTION AND NORMAL ORAL AND CLOACAL BACTERIAL FLORA SURVEY IN EASTERN HELLBENDERS (
    Musgrave KE; Hanley CS; Papich MG
    J Zoo Wildl Med; 2021 Apr; 52(1):90-96. PubMed ID: 33827165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of ceftazidime in elderly patients.
    Higbee MD; Swenson E; Gooch WM
    Clin Pharm; 1989 Jan; 8(1):59-62. PubMed ID: 2643501
    [No Abstract]   [Full Text] [Related]  

  • 24. [Probabilistic treatment with ceftazidime of severe infections in children].
    Bégué P
    Presse Med; 1988 Oct; 17(37):1985-7. PubMed ID: 2973603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and distribution of ceftazidime to milk after intravenous and intramuscular administration to lactating female dromedary camels (Camelus dromedarius).
    Goudah AM; Hasabelnaby SM
    J Am Vet Med Assoc; 2013 Aug; 243(3):424-9. PubMed ID: 23865886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftazidime in patients with impaired renal function. Studies on pharmacokinetics and nephrotoxicity.
    Thurmann-Nielsen E; Walstad RA; Dahl K; Hellum KB
    J Chemother; 1989 Jul; 1(4 Suppl):534-5. PubMed ID: 16312519
    [No Abstract]   [Full Text] [Related]  

  • 27. [Serum and cerebrospinal fluid kinetics of ceftazidime].
    Nadstawek J; Weil HP; Frenkel C; Kühnen E; Mauersberger W; Hörnchen U
    Immun Infekt; 1989 Dec; 17(6):212-6. PubMed ID: 2693344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of ceftazidime pharmacokinetic indices with therapeutic outcome in patients with cystic fibrosis.
    Munzenberger PJ; Hsu JM; Holliday SJ
    Pediatr Infect Dis J; 1993 Dec; 12(12):997-1001. PubMed ID: 8108228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
    Conil JM; Georges B; Ravat F; Ruiz S; Seguin T; Metsu D; Fourcade O; Saivin S
    Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advancing age and acute infection influence the kinetics of ceftazidime.
    Ljungberg B; Nilsson-Ehle I
    Scand J Infect Dis; 1989; 21(3):327-32. PubMed ID: 2667099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Continuous intravenous home treatment of airway infections using ceftazidime administration via portable pump in patients with cystic fibrosis; a multicenter study].
    Bakker W; Vinks AA; Mouton JW; de Jonge P; Verzijl JG; Heijerman HG
    Ned Tijdschr Geneeskd; 1993 Nov; 137(48):2486-91. PubMed ID: 8272124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Variability of ceftazidime pharmacokinetics in children with suppurative-septic diseases].
    Manuĭlov KK; Razumov VB; Ozerova IA
    Antibiot Khimioter; 1991 Apr; 36(4):30-2. PubMed ID: 1892431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increasing dose regimen in children with reactions to ceftazidime.
    Battersby NC; Patel L; David TJ
    Clin Exp Allergy; 1995 Dec; 25(12):1211-7. PubMed ID: 8821302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacokinetics of ceftazidime in children and newborn infants. Study in 14 patients and review of the literature].
    Quinet B; Bégué P
    Presse Med; 1988 Oct; 17(37):1921-4. PubMed ID: 2973586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Blumer JL; Saiman L; Konstan MW; Melnick D
    Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of ceftazidime after intravenous and intramuscular administration to domestic cats.
    Albarellos GA; Ambros LA; Landoni MF
    Vet J; 2008 Nov; 178(2):238-43. PubMed ID: 17768077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronokinetics of ceftazidime after intramuscular administration to dogs.
    Monfrinotti A; Ambros L; Montoya L; Prados AP; Rebuelto M
    Chronobiol Int; 2010 May; 27(3):549-59. PubMed ID: 20524800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of cephazolin, ceftazidime, and ceftriaxone distribution in nucleus pulposus.
    Yan D; Li J; Zhang Z; Zhu H
    Arch Orthop Trauma Surg; 2012 Jul; 132(7):969-73. PubMed ID: 22526195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Penetration of ceftazidime into intracranial abscess.
    Green HT; O'Donoghue MA; Shaw MD; Dowling C
    J Antimicrob Chemother; 1989 Sep; 24(3):431-6. PubMed ID: 2681122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of age on the pharmacokinetics of ceftazidime in acutely ill, adult patients.
    Ljungberg B; Nilsson-Ehle I
    Eur J Clin Pharmacol; 1988; 34(2):173-8. PubMed ID: 3289949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.